France
IXALTIS SA is a specialty pharmaceutical company that focuses on developing innovative treatments for genitourinary tract disorders. Founded in 2012 and headquartered in France, IXALTIS aims to address unmet medical needs in genitourinary (GU) disorders. The company has secured an exclusive worldwide license for three molecules from SANOFI: IXA-001, IXA-002, and IXA-003.
With a strong emphasis on proprietary therapeutics, IXALTIS has a specific focus on IXA-001 for use in urogenital and other disorders due to its unique mechanism of action. Their slogan, "DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS," reflects their commitment to providing solutions for diseases with limited or no satisfactory treatments.
The last recorded investment for IXALTIS was an $8.00M Venture Round investment on 31 May 2016. This round of funding saw participation from Principia SGR, IRDI, Sofimac Investment Managers, IXO Private Equity, and Pierre Olivier Goineau.
IXALTIS operates within the Biopharma, Biotechnology, Health Care, Health and Wellness, Medical Devices, and Pharmaceutical industries, positioning itself to make significant contributions to the advancement of treatments in these sectors. Overall, IXALTIS is poised to make a substantial impact in addressing unmet medical needs within the realm of genitourinary disorders.
